30-Second Takeaway
- Adaptive mHealth modestly reduces excessive gestational weight gain in overweight or obese pregnancies and is implementable in routine antenatal care.
- Remote blood pressure monitoring for high preeclampsia risk lowers visit burden without worsening maternal or perinatal outcomes.
- WPSI now prefers primary hrHPV screening and endorses self-collected hrHPV testing for average-risk women 30–65 years.
- Adjunct GLP-1 receptor agonists may substantially lower hysterectomy rates in fertility-sparing EIN/endometrial cancer management.
- Cesarean hysterotomy placement and endometrium-free closure likely influence long-term scar defects and placenta accreta spectrum risk.
Week ending April 25, 2026
Digital tools, precise risk stratification, and surgical technique tweaks reshape contemporary obstetric and gynecologic care
Adaptive mHealth program modestly lowers gestational weight gain in overweight and obese gravidas
In this cluster-randomized trial of 1,265 pregnant patients with BMI 25–<40, an adaptive mHealth lifestyle program reduced gestational weight gain versus standard care. Intervention patients gained less weight overall (mean 9.7 vs 10.6 kg), with a modest but significant weekly gain reduction of 0.03 kg. Fewer intervention patients exceeded IOM guidelines for weekly gestational weight gain, and more gained below guideline ranges. The intervention combined clinician motivational interviewing with app-based feedback, connected devices, education, and step-up coaching for accelerated gain.
Remote blood pressure monitoring safely reduces visit burden in pregnancies at high risk for preeclampsia
This multicenter noninferiority RCT randomized 270 high-risk pregnant women to remote versus clinic-based blood pressure monitoring in addition to standard care. The composite perinatal outcome did not differ between groups, with a hazard ratio of 1.0 and wide confidence intervals. Maternal secondary outcomes were also similar, suggesting no signal of harm with remote monitoring. Remote monitoring reduced total antenatal visits and planned outpatient appointments compared with usual care, improving healthcare utilization.
WPSI endorses primary and self-collected hrHPV testing for average-risk cervical cancer screening
WPSI now recommends cervical cancer screening for average-risk women 21–65, emphasizing primary hrHPV testing for those aged 30–65. For ages 21–29, cytology alone every 3 years remains the recommendation; co-testing is not advised in this group. For ages 30–65, preferred options are primary hrHPV or co-testing every 5 years, with cytology alone every 3 years acceptable when hrHPV is unavailable. New evidence shows primary hrHPV detects more precancer than cytology, and patient-collected hrHPV samples have similar accuracy to clinician-collected.
GLP-1 receptor agonists plus progestin reduce hysterectomy risk in fertility-sparing EIN and endometrial cancer care
This propensity-matched cohort examined women ≤45 years with EIN or endometrial cancer undergoing fertility-sparing progestin therapy with or without GLP-1 receptor agonists. After matching 432 women per group, 18‑month hysterectomy occurred in 10.2% receiving GLP-1RA plus progestin versus 23.4% with progestin alone. Adjunct GLP-1RA therapy was associated with a 59% lower hysterectomy hazard (HR 0.41, 95% CI 0.29–0.58). Risk reduction was consistent across subgroups, including younger patients, cancer diagnoses, progestin types, and GLP-1RA agents.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.